I
Ian Glaspole
Researcher at Monash University
Publications - 145
Citations - 6438
Ian Glaspole is an academic researcher from Monash University. The author has contributed to research in topics: Idiopathic pulmonary fibrosis & Interstitial lung disease. The author has an hindex of 30, co-authored 121 publications receiving 5082 citations. Previous affiliations of Ian Glaspole include Monash University, Clayton campus & National Health and Medical Research Council.
Papers
More filters
Journal ArticleDOI
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis
Talmadge E. King,Williamson Z. Bradford,Socorro Castro-Bernardini,Elizabeth A. Fagan,Ian Glaspole,Marilyn K. Glassberg,Eduard Gorina,Peter Hopkins,David Kardatzke,Lisa Lancaster,David J. Lederer,Steven D. Nathan,Carlos Alberto de Castro Pereira,Steven A. Sahn,Robert Sussman,Jeffrey J. Swigris,Paul W. Noble +16 more
TL;DR: Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis.
Journal ArticleDOI
Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials
Paul W. Noble,Carlo Albera,Williamson Z. Bradford,Ulrich Costabel,Roland M. du Bois,Elizabeth A. Fagan,Robert S. Fishman,Ian Glaspole,Marilyn K. Glassberg,Lisa Lancaster,David J. Lederer,Jonathan A. Leff,Steven D. Nathan,Carlos Alberto de Castro Pereira,Jeffrey J. Swigris,Dominique Valeyre,Talmadge E. King +16 more
TL;DR: Analysis of data from three phase 3 trials demonstrated that treatment with pirfenidone for 1 year resulted in clinically meaningful reductions in disease progression in patients with IPF.
Journal ArticleDOI
Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis
Steven D. Nathan,Carlo Albera,Williamson Z. Bradford,Ulrich Costabel,Ian Glaspole,Marilyn K. Glassberg,David Kardatzke,Monica Daigl,Klaus Uwe Kirchgaessler,Lisa Lancaster,David J. Lederer,Carlos Alberto de Castro Pereira,Jeffrey J. Swigris,Dominique Valeyre,Paul W. Noble +14 more
TL;DR: Several analytic approaches demonstrated that pirfenidone therapy is associated with a reduction in the relative risk of mortality compared with placebo over 120 weeks.
Journal ArticleDOI
The evidence of benefits of exercise training in interstitial lung disease: a randomised controlled trial
Leona M. Dowman,Christine F McDonald,Catherine J. Hill,Annemarie L. Lee,Kathryn Barker,Claire Boote,Ian Glaspole,Nicole S L Goh,Anne M. Southcott,Angela T Burge,Rebecca Gillies,Alicia Martin,Anne E Holland +12 more
TL;DR: Exercise training is effective in patients across the range of ILDs, with clinically meaningful benefits in asbestosis and IPF, and sustained treatment effects favour those with milder disease.
Journal ArticleDOI
Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry.
Helen E. Jo,Helen E. Jo,Ian Glaspole,Ian Glaspole,Christopher Grainge,Nicole S L Goh,Nicole S L Goh,Peter Hopkins,Yuben Moodley,Paul N. Reynolds,Sally Chapman,E. Haydn Walters,Christopher Zappala,Heather Allan,Gregory J. Keir,Andrew Hayen,Wendy A Cooper,Annabelle Mahar,Samantha Ellis,Sacha Macansh,Tamera J. Corte,Tamera J. Corte +21 more
TL;DR: Data from the Australian IPF registry shows anti-fibrotic therapy and baseline physiology predict survival in IPF, and patients receivingAnti-f fibrotic medications had better survival than those not on anti- fibrotics medications, independent of underlying disease severity.